PRCT · CIK 0001588978 · operating
PROCEPT BioRobotics develops and commercializes robotic systems for minimally invasive urologic surgery, specifically targeting the treatment of benign prostatic hyperplasia (BPH). The company's primary product is the AquaBeam Robotic System, an image-guided surgical platform that enables urologists to perform Aquablation therapy—a water-jet based ablation technique for removing excess prostate tissue. The company also offers the HYDROS Robotic System, which provides similar Aquablation capabilities for treating lower urinary tract symptoms in male BPH patients. Both systems represent the company's core technology platform focused on reducing tissue trauma and recovery time compared to traditional surgical approaches.
The company generates revenue primarily through the sale of robotic systems and related consumables and services to hospitals and surgical centers in the United States and international markets. PROCEPT BioRobotics was incorporated in Delaware in 2007 and maintains its operational headquarters in San Jose, California. As of its Nasdaq listing, the company maintained a market capitalization of approximately $1.3 billion, reflecting its position as a specialized medical device manufacturer in the surgical robotics segment.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-1.72 | $-1.72 | +1.7% | |
| 2024 | $-1.75 | $-1.75 | +21.9% | |
| 2023 | $-2.24 | $-2.24 | -14.3% | |
| 2022 | $-1.96 | $-1.96 | +46.0% | |
| 2021 | $-3.63 | $-3.63 | — |